StockWatch
·

Research Reports

Wed, 11 Nov
AGARWALEYEDr. Agarwals Health Care Ltd

Expansion Blitz Masks Margin Squeeze; the Real Test is H2

facility expansion · surgical centers · greenfield ramp

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
AGARWALEYEDr. Agarwals Health Care Ltd

Facility expansion and execution drive 56% PAT growth; capex guidance hiked

greenfield expansion · surgical facility ramp-up · strong SSSG

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
HALEOSLABSSMS Lifesciences India Ltd

Haleos Labs Q2 FY27: consolidated PAT falls 73% YoY on margin squeeze, revenue up 12%

api manufacturing · margin compression · subsidiary loss

ResultsQ2 FY273 minPharma & Healthcare
AUROPHARMAAUROBINDO PHARMA LTD.

Record revenue, flat margins: the Lannett integration story Q2 is hiding

Lannett integration · Margin accretion · US growth

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
AUROPHARMAAUROBINDO PHARMA LTD.

Record Q2 growth 24% YoY, but Lannett drag and cost pressures cap near-term accretion

Lannett integration · margin guidance · US growth

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
GKSLGujarat Kidney and Super Speciality Ltd

Strong Growth Masks Integration Drag and Cash Flow Anxiety

acquisition-led growth · cash flow lag · working capital drain

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
GKSLGujarat Kidney and Super Speciality Ltd

Strong Q2 growth masked by integration drag and guidance silence

acquisition-led growth · margin expansion · working capital drag

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
SHILPAMEDSHILPA MEDICARE LTD.

Record revenue, margin pressure emerging; CDMO momentum solid but execution uncertain

CDMO_growth · Biologics_inflection · Margin_compression

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
KIMSKrishna Institute of Medical Sciences Ltd

40% Growth, 3.6% Earnings—the Margin Test Kims Must Pass

margin compression · unit ramp-up · doubtful debt

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
KIMSKrishna Institute of Medical Sciences Ltd

40% revenue growth, margin headwind from ramp-ups and insurance delays

unit stabilization · margin compression · insurance empanelment

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
GUJTHEMGUJARAT THEMIS BIOSYN LTD.

Acquisition Integration Takes Center Stage as GTBL Reports Q2—Margins and MicroBiopharm Synergies in Focus

CDMO · fermentation · MicroBiopharm

Result previewQ2 FY273 minPharma & Healthcare
Tue, 10 Nov
FORTISFORTIS HEALTHCARE LTD.

Revenue Up 17%, Profit Down 2% — The Execution Test Begins

bed expansion · margin pressure · ESOP impact

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
FORTISFORTIS HEALTHCARE LTD.

Strong growth, margin pressure; PAT declined despite 17% revenue rise

bed expansion · revenue growth · margin pressure

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
SMSPHARMASMS PHARMACEUTICALS LTD.

Strong Execution on Backward Integration — But Can It Hold Through the Commodity Cycle?

backward integration · ibuprofen pricing · capex execution

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
SMSPHARMASMS PHARMACEUTICALS LTD.

Strong execution raises FY27 guidance; capex and peptides emerging risks

backward integration · peptides expansion · ibuprofen volumes

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
SURAKSHASuraksha Diagnostic Ltd

Suraksha Diagnostic Q2FY27: consolidated PAT +67% YoY to ₹15 Cr, margins expand to ~36%

diagnostics · healthcare services · margin expansion

ResultsQ2 FY273 minPharma & Healthcare
INDSWFTLABIND-SWIFT LABORATORIES LTD.

Execution-led growth on track; margin recovery delayed to H2

CDMO scaling · export 83% · Viatris partnership

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
APLLTDALEMBIC PHARMACEUTICALS LTD.

Bosutnib exclusivity inflates 36% growth; durable pipeline beckons

US generics momentum · bosutnib exclusivity cliff · US branded ramp-up

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
LALPATHLABDr. Lal PathLabs Ltd

High-Teens Growth Has a 4-Quarter Expiry Date

diagnostics · revenue-growth · margin-pressure

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
LALPATHLABDr. Lal PathLabs Ltd

Strong growth with margin headwinds; pricing inflection ahead

19.6% revenue growth · 32.1% EBITDA margin · acquisitions

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
MEDANTAGlobal Health Ltd

The Margin Question Management Won't Answer

Noida · EBITDA breakeven · margin expansion

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
MEDANTAGlobal Health Ltd

Noida breakeven early validates scale-up model; capex raised to ₹6,000 Cr

Noida EBITDA breakeven · Cluster 2 growth · capacity expansion

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
JSLLJeena Sikho Lifecare Ltd

Momentum Test: Can Growth Sustain as Hospital Ramp Hits Speedbumps?

healthcare · ayurveda · hospital expansion

Result previewQ2 FY273 minPharma & Healthcare
KOVAIKOVAI MEDICAL CENTER & HOSPITAL LTD.

Margin expansion to carry second quarter; capex ramp weighs balance sheet

healthcare · margin expansion · capex

Result previewQ2 FY273 minPharma & Healthcare
INNOVACAPInnova Captab Ltd

Momentum test: Can Innova Captab sustain Q1's 34% growth sprint?

CDMO · branded generics · margin expansion

Result previewQ2 FY273 minPharma & Healthcare
VIYASHSEQUENT SCIENTIFIC LTD.

API Upswing & Margin Expansion—The FY27 Inflection Point

earnings preview · margin expansion · API growth

Result previewQ2 FY273 minPharma & Healthcare
09 Nov 2026
MAXHEALTHMax Healthcare Institute Ltd

Revenue Soars 20% but Profit Halts—a Margin Collapse Under Regulatory & Brownfield Drag

margin compression · brownfield drag · oncology headwind

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
MAXHEALTHMax Healthcare Institute Ltd

Revenue growth masks 15.6% PAT decline; margin pressure persists

margin compression · brownfield ramp-up · oncology headwind

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
HCGHealthCare Global Enterprises Ltd

13% Revenue, 55% Profit Collapse: The Provision Gap HCG Won't Repeat

oncology · margin regulation · price caps

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
HCGHealthCare Global Enterprises Ltd

13% growth, 55% PAT collapse; regulatory headwind looms

revenue growth slowing · PAT decline masked by adjustments · price cap risk

TranscriptDeep diveQ2 FY276 minPharma & Healthcare